New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness
about
Safety and Efficacy of Under-dosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation.The Reversal of Direct Oral Anticoagulants in Animal Models.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsMeta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US.Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral AnticoagulantsMajor bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United StatesComparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillationOral surgery during therapy with anticoagulants-a systematic review.Clinical development of rivaroxaban: emerging new clinical evidences?Edoxaban: a review in nonvalvular atrial fibrillation.Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.Betrixaban - the next direct factor Xa inhibitor?Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation.The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on Bleeding and Coagulation Management in Neurostimulation Devices.Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan.Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance.Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.Determination of Rivaroxaban in Human Plasma by Solid-Phase Extraction-High Performance Liquid Chromatography.Direct Oral Anticoagulants for Very Elderly People With Atrial Fibrillation: Efficacy and Safe Enough?Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer.Evaluating the Usability and Usefulness of a Mobile App for Atrial Fibrillation Using Qualitative Methods: Exploratory Pilot Study.Development and validation of a questionnaire to self-assess patient knowledge of direct oral anticoagulants (KODOA-test)
P2860
Q30490526-B9608F31-060B-4999-9F5C-32932C9CC085Q30491580-200AC048-6912-4386-86C8-689DD3B35CA2Q35674404-C3DEEEE2-080B-496D-88C5-96B9192CEF8DQ36172403-3F573C9C-E0FD-443A-B171-90C9F7400D8FQ36940076-89D4D2D5-5B5D-4393-9E83-7DF4F1169FE8Q37253651-EFFE96D6-3A89-4F00-8F99-5015A58A0D2EQ37456586-A5DD51AD-3217-42FA-A9D1-DA389959E8CEQ37672931-504F9DD7-3985-4745-A2AC-BCD0077B1C51Q38270037-8FA7A9D6-B31A-4140-AB0D-874D2AE738C1Q38537785-532442E2-4DA0-477D-8F58-EA1B3F9726ADQ38586582-D26DB165-F781-4036-A316-49D4E4404318Q38588261-7592B55F-8E12-4221-8895-9C2DA8E403ECQ38685824-43E5ECED-FB53-497D-B04C-272456DD26E8Q38792322-E8379835-C5AF-43F4-B27C-BA688CC4D8FBQ38799138-8923379A-F93D-4DA0-9128-1C16D2DC1C93Q38812464-651AB0B8-4ED4-49B5-84DD-4AAD883785D5Q39000179-4FA3AF9B-4667-47E4-A7AF-C76E8D1E2429Q39037268-748C7401-1B0B-4E38-A265-D975759A54DCQ39161825-6879D2BC-CE83-4FB4-A5B5-9D57160E5A0CQ46050727-D0F228ED-5B89-4E91-B323-994B79CCEA02Q47594064-8A480901-E333-4F83-9621-C9C251A5DB1CQ48191307-122CF1DE-9D0A-47D2-B70D-66FAD69F6C8BQ50193651-8BD7288E-B8B0-4000-9ABF-DA6A6D02D014Q53357678-1D114165-C6B5-428C-90F7-DEABFD455CD2Q53652929-3BF306F6-7031-4E30-BA4F-855D8B21F59CQ54937563-02E80069-2170-4FAE-931C-325AFAC53847Q55031739-F0897014-CA88-4E8A-B612-EFC5FE6C0927Q55242708-E76EF552-E51A-4303-B451-E7C5C48C107AQ57616533-3E684C5E-67F6-46AC-A7F6-0AADF4B537C8
P2860
New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
New oral anticoagulants in pat ...... f life, and cost effectiveness
@ast
New oral anticoagulants in pat ...... f life, and cost effectiveness
@en
New oral anticoagulants in pat ...... f life, and cost effectiveness
@nl
type
label
New oral anticoagulants in pat ...... f life, and cost effectiveness
@ast
New oral anticoagulants in pat ...... f life, and cost effectiveness
@en
New oral anticoagulants in pat ...... f life, and cost effectiveness
@nl
prefLabel
New oral anticoagulants in pat ...... f life, and cost effectiveness
@ast
New oral anticoagulants in pat ...... f life, and cost effectiveness
@en
New oral anticoagulants in pat ...... f life, and cost effectiveness
@nl
P2860
P921
P3181
P356
P1476
New oral anticoagulants in pat ...... f life, and cost effectiveness
@en
P2093
Edelgard Lindhoff-Last
Helen Mani
P2860
P304
P3181
P356
10.2147/DDDT.S45644
P407
P5008
P577
2014-01-01T00:00:00Z
2014-06-17T00:00:00Z